Abstract
With age, eyesight declines and the vulnerability to age-related eye diseases such as glaucoma, cataract, macular degeneration and diabetic retinopathy increases. With the aging of the global population, the prevalence of these diseases is projected to increase, leading to reduced quality of life and increased healthcare cost. In the following, we built an eye age predictor by training convolutional neural networks to predict age from 175,000 eye fundus and optical coherence tomography images (R-Squared=83.6+-0.6%; root mean squared error=3.34+-0.07 years). We used attention maps to identify the features driving the eye age prediction. We defined accelerated eye aging as the difference between eye age and chronological age and performed a genome wide association study [GWAS] on this phenotype. Accelerated eye aging is 28.2+-1.2% GWAS-heritable, and is associated with 255 single nucleotide polymorphisms in 122 genes (e.g HERC2, associated with eye pigmentation). Similarly, we identified biomarkers (e.g blood pressure), clinical phenotypes (e.g chest pain), diseases (e.g cataract), environmental variables (e.g sleep deprivation) and socioeconomic variables (e.g income) associated with our newly defined phenotype. Our predictor could be used to detect premature eye aging in patients, and to evaluate the effect of emerging rejuvenation therapies on eye health.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NIEHS R00 ES023504 NIEHS R21 ES25052. NIAID R01 AI127250 NSF 163870 MassCATS, Massachusetts Life Science Center Sanofi The funders had no role in the study design or drafting of the manuscript(s).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Harvard internal review board (IRB) deemed the research as non-human subjects research (IRB: IRB16-2145).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
We used the UK Biobank (project ID: 52887). The code can be found at https://github.com/Deep-Learning-and-Aging. The results can be interactively and extensively explored at https://www.multidimensionality-of-aging.net/. We will make the biological age phenotypes available through UK Biobank upon publication. The GWAS results can be found at https://www.dropbox.com/s/59e9ojl3wu8qie9/Multidimensionality_of_aging-GWAS_results.zip?dl=0.
https://github.com/Deep-Learning-and-Aging
https://www.multidimensionality-of-aging.net/
https://www.dropbox.com/s/59e9ojl3wu8qie9/Multidimensionality_of_aging-GWAS_results.zip?dl=0